Adagio Medical Publishes Feasibility Study Results

Adagio Medical Holdings Inc. (NASDAQ:ADGM) on February 4 announced publication of results from a US Early Feasibility Study evaluating ultralow temperature cardiac ablation (ULTC) for scar-related ventricular tachycardia. The multicenter four-site study enrolled 20 patients and reported no major adverse events at 7 or 30 days, 92.9% non-inducibility, and favorable 24-week clinical outcomes.